cell therapy

BioCardia secured FDA alignment on two regulatory routes for its Helix transendocardial delivery catheter, with the agency backing simultaneous approval with CardiAMP cell therapy.

Mesoblast reports Q3 FY2026 Ryoncil revenues of $30.3M, approaching $100M cumulative sales, while reducing operating cash spend and strengthening balance sheet.

Cell culture media bags market projected to reach $2.28B by 2035 from $1.30B in 2025, growing at 5.8% CAGR amid biotech manufacturing expansion.

Immatics' PRAME-directed TCR therapy achieves deep remission in advanced pediatric cancer patient, validating engineered T-cell approach in solid tumors.

IOB scientists unveil MitoCatch, engineered technology delivering healthy mitochondria to damaged cells. Early data shows improved cell survival in disease models.

Iovance's Amtagvi cancer therapy targets $1B+ revenue by 2030 amid strong early growth, but faces manufacturing cost and regulatory risks.

Longevity biotech sector surges toward $29.7B market by 2034 as companies advance cell therapies for age-related diseases, with multiple clinical programs showing promising results.

Artiva Biotherapeutics to present AlloNK cell therapy pipeline at Needham Healthcare Conference on April 15, 2026, advancing three ongoing autoimmune disease trials.

Mesoblast receives IND clearance to proceed directly to registrational trial for Ryoncil in Duchenne muscular dystrophy, potentially accelerating path to market approval.

Regenerative medicine market projected at $578B faces manufacturing bottleneck as Avaí Bio advances Master Cell Bank solution enabling scalable, off-the-shelf cell therapy production.

Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.

ProKidney reports $270M cash reserves extending operations to mid-2027, achieves FDA alignment on accelerated approval pathway for rilparencel with Phase 3 enrollment progressing ahead of schedule.

Avaí Bio begins manufacturing genetically modified cells overexpressing α-Klotho protein, an anti-aging compound that naturally declines 50% after age 40, advancing its Cell-in-a-Box platform.

Mesoblast appoints veteran biotech executive Dr. Teresa Montagut as Head of Clinical Development, signaling acceleration in cell therapy pipeline expansion and Ryoncil® indication broadening.

Iovance shows 60.6% fiscal 2025 revenue growth for its personalized cancer therapy Amtagvi, but faces manufacturing complexity and profitability challenges ahead.

Cell therapy companies achieve major manufacturing and clinical milestones, positioning sector for explosive growth as global market targets $8.2 billion by 2026.

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.

Artiva Biotherapeutics appoints veteran pharma executive Thad Huston as CFO with 30+ years experience, ahead of key FDA feedback and clinical data milestones.

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.

12+ companies advance iPSC-derived NK cell therapies for cancer treatment. Century Therapeutics and Fate Therapeutics report promising clinical progress in this expanding immunotherapy field.